
Opinion|Videos|October 14, 2023
Tazemetostat: Targeting EZH2 in R/R Follicular Lymphoma
Hematologist/oncologists describe the rationale for treatment approaches targeting EZH2 and discuss recent guideline updates surrounding the role of tazemetostat and EZH2 testing in patients with follicular lymphoma.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
3
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
4
What Does an End-of-Life Doula Do for Patients With Cancer?
5





!["I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/11e93c561a9ff98f731b152d7f48e6f792831864-1000x1000.jpg?w=350&fit=crop&auto=format)



















































